VARS coalition screens 2.5 million drivers to put vision on India’s road safety agenda

IMT News Desk
IMT News Desk
· 3 min read
The Vision and Road Safety (VARS) coalition has screened 2.5 million drivers and dispensed over 1.17 million eyeglasses, urging that clear vision be recognised as a core pillar of India’s road safety strategy.

The Vision and Road Safety (VARS) Conference in Mumbai has highlighted eyesight as a critical yet under-recognised factor in preventing road crashes, with the coalition announcing that about 2.5 million drivers have been screened for vision impairments till February 2026 and more than 1.17 million pairs of eyeglasses dispensed. Additional screenings planned for 3,00,000 drivers across India aim to further expand access to essential eye care and improve road safety outcomes.

Globally, road traffic crashes claim approximately 1.19 million lives every year, making them one of the leading causes of mortality and disability worldwide. Despite having only about 1% of the world’s motor vehicles, India accounts for nearly 11% of global road traffic deaths, with 4.87 lakh road accidents in 2024 causing 1.77 lakh fatalities and an estimated economic loss of about 3% of GDP.

Research presented at the conference underscored the strong link between poor vision and crash risk. Drivers with cataracts are 2.5 times more likely to be involved in at-fault crashes, while studies indicate that over 26% of truck drivers have refractive error, yet only 47% of those prescribed glasses actually use them. Further evidence shows that 81% of drivers with at least one visual function defect have been involved in a road traffic accident, underscoring the urgent need to integrate eyesight into mainstream road safety strategies.

To address this gap, the VARS Conference, a collaborative initiative by India Vision Institute, Mission for Vision, Sightsavers India, and VisionSpring Foundation, convened experts and stakeholders from the transport, health, research, and development sectors at Mumbai’s Yashwantrao Chavan Centre. The meeting brought together over 100 participants, including government representatives, road safety experts, eye health professionals, public health specialists, transport authorities, researchers, and civil society organisations.

A central focus of the deliberations was a call to recognise eye health and clear vision as the fifth “E” of Road Safety, alongside Engineering, Enforcement, Education, and Emergency Medical Services. Experts stressed that systematic vision screening, timely corrective eyewear, and policy-level integration of eye health could play a crucial role in reducing preventable crashes and associated deaths and injuries.

The conference also explored opportunities to embed vision screening and eye health considerations into national and state road safety frameworks, in line with the UN Decade of Action for Road Safety 2021-2030, which targets a 50% reduction in road traffic deaths and injuries. Through expert discussions and knowledge exchange, participants shared research insights, implementation experiences, and best practices, while identifying ways to strengthen collaboration between transport authorities, health systems, employers, and civil society.

Representatives of the VARS Alliance said, “Safe driving begins with clear vision, yet eye health is still often overlooked in road safety systems. The VARS Conference brings together stakeholders from the health, transport, and development sectors to advance this conversation. If we are serious about preventing road crashes and protecting lives, vision screening and access to corrective care must become a routine part of driver health and road safety mechanisms. By working together to strengthen vision screening programmes and ensure drivers have access to quality eye health, we can help drivers see clearly and make our roads safer for everyone.”

Read Next

‘One Nation, One Emergency Helpline’ Proposal for Stroke Care Gains Momentum at FICCI Meet
News
April 16, 2026

‘One Nation, One Emergency Helpline’ Proposal for Stroke Care Gains Momentum at FICCI Meet

India’s stroke crisis demands urgent action, and the Indian Stroke Association (ISA) is leading the charge with a bold proposal for a unified national helpline. The ISA presented a comprehensive plan to strengthen stroke care delivery at a FICCI-hosted meeting attended by policymakers, healthcare leaders, and clinical experts. The plenary session, “Strengthening Stroke Care Delivery,” […]
Article by: IMT News Desk
Ivory raises fresh capital to strengthen deep tech offerings
News
April 16, 2026

Ivory raises fresh capital to strengthen deep tech offerings

Ivory, a brain health platform focused on early cognitive screening, has raised $1M in fresh funding, onboarding new investors to deepen its product, clinical and IP capabilities. The round saw participation from Draper Associates, a global venture capital firm with a strong focus on biotech and healthtech, along with SAGE Venture Fund, an AIF fund launched […]
Article by: IMT News Desk
Rubicon Research Enters Indian CNS Formulations Market with Strategic Acquisition
News
April 16, 2026

Rubicon Research Enters Indian CNS Formulations Market with Strategic Acquisition

Rubicon Research Limited today announced the acquisition of an 85% equity ownership in Arinna Lifesciences Limited from its current shareholders. With a portfolio of over 60 brands in chronic therapies, Arinna is one of the few domestic formulation companies principally focused on drugs treating conditions of the central nervous system (“CNS”) with more than 4,000 […]
Article by: IMT News Desk
MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide
News
April 16, 2026

MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide

MSN Laboratories has launched SEMABEST, its semaglutide brand, in the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO). SEMABEST is priced at nearly 50% lower than the innovator drug, significantly improving affordability and patient access. The therapy is available as a pre-filled pen for subcutaneous administration. In this evolving landscape, SEMABEST […]
Article by: IMT News Desk